Effect of an intervention on the features of adverse drug reactions spontaneously reported in a hospital

European Journal of Clinical Pharmacology

Volumn 66, Issue 9, 2010, Pages 937-945

  Cereza, Gloria ^a,b   Agustí, Antonia ^a,c,d   Pedrós, Consuelo ^e   Vallano, Antonio ^e,f   Aguilera, Cristina ^a,c   Danés, Immaculada ^a,c,d   Vidal, Xavier ^a,c,d   Arnau, Josep Maria ^e,f  

^a Fundacion Institut Catala de Farmacologia   (Spain)

^b Catalan Centre of Pharmacovigilance   (Spain)

^c Section of Neuroradiology   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Adverse drug reactions reporting systems; Drug toxicity; Hospital; Intervention studies; Pharmacovigilance

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; AMIODARONE; AMOXICILLIN PLUS CLAVULANIC ACID; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; ANTIMYCOBACTERIAL AGENT; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; CORTICOSTEROID; DIPYRONE; DIURETIC AGENT; DROTRECOGIN; ENALAPRIL; ENOXAPARIN; IMMUNOSTIMULATING AGENT; IMMUNOSUPPRESSIVE AGENT; LEVOFLOXACIN; NEW DRUG; PHENYTOIN; THIETHYLPERAZINE; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANAPHYLACTIC SHOCK; ANGIONEUROTIC EDEMA; ARTICLE; ATRIOVENTRICULAR BLOCK; BRAIN DISEASE; BRAIN HEMORRHAGE; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CHOLESTATIC HEPATITIS; CONSULTATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG ERUPTION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSKINESIA; DYSTONIA; ENDOCRINE DISEASE; ERYTHEMA; EXTRAPYRAMIDAL SYNDROME; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE MANAGEMENT; HEART ARREST; HEART FAILURE; HEART VENTRICLE FIBRILLATION; HEMATOLOGIC DISEASE; HEMATOMA; HEMOPERITONEUM; HEPATITIS; HOSPITAL PHYSICIAN; HUMAN; HYPERTHYROIDISM; HYPOTENSION; LARYNX EDEMA; LIVER DISEASE; LONGITUDINAL STUDY; MACULOPAPULAR RASH; MALE; MEDICAL CARE; MENTAL DISEASE; METABOLIC DISORDER; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; QT PROLONGATION; RESPIRATORY TRACT DISEASE; RETROPERITONEAL HEMATOMA; RETROPERITONEAL HEMORRHAGE; SEX DIFFERENCE; SIDE EFFECT; SKIN MANIFESTATION; TEACHING HOSPITAL; THROMBOCYTOPENIA; TORSADE DES POINTES; URINARY TRACT DISEASE; URTICARIA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG TOXICITY; HOSPITALISTS; HOSPITALS, UNIVERSITY; HUMANS; LONGITUDINAL STUDIES; SEVERITY OF ILLNESS INDEX; SPAIN;

EID: 77956192371     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0856-8     Document Type: Article

References (28)

1. DK Wysowski L Swartz 2005 Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions Arch Intern Med 165 1363 1369 10.1001/archinte.165.12.1363 15983284
2. JK Aronson 2007 Adverse drug reactions-no farewell to harms Br J Clin Pharmacol 63 131 135 10.1111/j.1365-2125.2006.02860.x 17274787
3. PA Thürmann 2001 Methods and systems to detect adverse drug reactions in hospitals Drug Saf 24 961 968 10.2165/00002018-200124130-00003 11735652
4. MD Rawlins 1995 Pharmacovigilance; paradise lost, regained or postponed? The William Withering Lecture 1994 J R Coll Physicians Lond 29 41 49 1:STN:280:DyaK2M3lslaitQ%3D%3D 7738878
5. A Vallano G Cereza C Pedros A Agusti I Danes C Aguilera JM Arnau 2005 Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital Br J Clin Pharmacol 60 653 658 10.1111/j.1365-2125.2005.02504.x 1:STN:280:DC%2BD2MnisFSrsQ%3D%3D 16305591
6. Y Moride F Haramburu AA Requejo B Begaud 1997 Under-reporting of adverse drug reactions in general practice Br J Clin Pharmacol 43 177 181 10.1046/j.1365-2125.1997.05417.x 1:STN:280:DyaK2s3islSqsg%3D%3D 9131950
7. A Figueiras MT Herdeiro J Polonia JJ Gestal-Otero 2006 An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial JAMA 296 1086 1093 10.1001/jama.296.9.1086 1:CAS:528:DC%2BD28XptlKjsLs%3D 16954488
8. M Nazario JF Feliu GC Rivera 1994 Adverse drug reactions: the San Juan Department of Veterans Affairs Medical Center experience Hosp Pharm 29 244 250 1:STN:280:DyaK2c7ptlCgsg%3D%3D 10171808
9. HD Scott A Thacher-Renshaw SE Rosenbaum WJ Waters Jr M Green LG Andrews GA Faich 1990 Physician reporting of adverse drug reactions. Results of the Rhode Island adverse drug reaction reporting project JAMA 263 1785 1788 10.1001/jama.263.13.1785 1:STN:280:DyaK3c7ovFCjtg%3D%3D 2313850
10. J Fincham 1989 A statewide program to stimulate reporting of adverse drug reactions J Pharm Pract 2 239 244 10.1177/089719008900200407
11. P McGettigan J Golden RM Conroy N Arthur J Feely 1997 Reporting of adverse drug reactions by hospital doctors and the response to intervention Br J Clin Pharmacol 44 98 100 10.1046/j.1365-2125.1997.00616.x 1:STN:280: DyaK2szotlWisQ%3D%3D 9241104
12. BJ Kimelblatt SH Young PM Heywood AR Mandala S Gendelman B Mehl 1988 Improved reporting of adverse drug reactions Am J Hosp Pharm 45 1086 1089 1:STN:280:DyaL1c3pt1arug%3D%3D 3400650
13. C Pedrós A Vallano G Cereza G Mendoza-Aran A Agustí C Aguilera I Danés X Vidal JM Arnau 2009 An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians. A time series analysis in Spain Drug Saf 32 77 83 10.2165/00002018-200932010-00007 19132807
14. I Maistrello M Morgutti M Maltempi M Dantes 1995 Adverse drug reactions in hospitalized patients: an operational procedure to improve reporting and investigate underreporting Pharmacoepidemiol Drug Saf 4 101 106 10.1002/pds.2630040206
15. AR Cox C Anton CHF Goh M Easter NJ Langford RE Ferner 2001 Adverse drug reactions in patients admitted to hospital identified by discharge ICD-10 codes and by spontaneous reports Br J Clin Pharmacol 52 337 339 10.1046/j.0306-5251. 2001.01454.x 1:STN:280:DC%2BD3Mrht1Kkug%3D%3D 11560569
16. A Ortega A Aguinagalde C Lacasa I Aquerreta M Fernández- Benítez LM Fernández 2008 Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system Ann Pharmacother 42 1491 1496 10.1345/aph.1L130 18780808
17. J Jose PGM Rao 2006 Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital Pharmacol Res 54 226 233 10.1016/j.phrs.2006.05.003 16781163
18. R Arulmani SD Rajendran B Suresh 2007 Adverse drug reaction monitoring in a secondary care hospital in South India Br J Clin Pharmacol 65 210 216 10.1111/j.1365-2125.2007.02993.x 17662089
19. S Baniasadi F Fahimi G Shalviri 2008 Developing an adverse drug reaction reporting system at a teaching hospital Basic Clin Pharmacol Toxicol 102 408 411 10.1111/j.1742-7843.2008.00217.x 1:CAS:528:DC%2BD1cXksFaqtb4%3D 18312492
20. R Edwards 1997 Adverse drug reactions: finding the needle in the haystack Br Med J 315 500 1:STN:280:DyaK2svmvFyrsw%3D%3D
21. Commission Directive 2000/38/EC of 5 June 2000 amending Chapter Va (Pharmacovigilance) of Council Directive 75/319/EEC on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products. Official Journal of the European Communities 10.6.2000: L139/28-L139/30. Available from http://eur-lex.europa.eu/LexUriServ/LexUriServ. do?uri=OJ:L:2000:139:0028:0030:EN:PDF. Accessed 10 September 2009
22. Capellà D, Laporte J-R (1993) La notificación espontánea de reacciones adversas a medicamentos. In: Laporte J-R, Tognoni G (eds) Principios de epidemiología del medicamento, 2nd edn. Masson-Salvat, Barcelona, pp 147-170
23. Spanish Agency of Medicines and Health Products. Product Information. Gelafundina®. https://sinaem4.agemed.es/consaem/especialidad.do?metodo= verFichaWordPdf&codigo=61627&formato=pdf&formulario=FICHAS. Accessed 10 September 2009
24. Spanish Agency of Medicines and Health Products. Informative note. Recommendations for the withdrawal of the treatment with Agreal® (Veralipride). http://www.agemed.es/actividad/alertas/docs/NI-2005-15-AGREAL. pdf. Accessed 10 September 2009
25. European Medicines Agency. Questions and answers on the recommendation to withdraw the marketing authorisation of veralipride. http://www.emea.europa.eu/ pdfs/human/referral/agreal/29946807en.pdf. Accessed 10 September 2009
26. European Medicines Agency. Xigris. Procedural steps taken and scientific information after the authorisation. Changes made after 01/10/2004. http://www.emea.europa.eu/humandocs/PDFs/EPAR/xigris/H-396-en8b.pdf. Accessed 10 September 2009
27. R Uppal R Jhaj S Malhotra 2000 Adverse drug reactions among inpatients in a north Indian referral hospital Natl Med J India 13 16 18 1:STN:280: DC%2BD3c3gslOksQ%3D%3D 10743370
28. S Lugardon K Desboeuf P Fernet J-L Monstastruc M Lapeyre-Mestre 2006 Using a capture-recapture method to assess the frequency of adverse drug reactions in a French university hospital Br J Clin Pharmacol 62 225 231 10.1111/j.1365-2125.2006.02633.x 16842398